Granted Patent B2

US 9,931,414 · App. 14/434,816 · Granted Apr 3, 2018

Abstract

Claims (19)

1. A conjugate of formula

where Ab is an antibody which is an antibody that binds to CD19, the antibody comprising a VH domain having the sequence of SEQ ID NO. 2, optionally further comprising a VL domain having the sequence of SEQ ID NO. 8; and

wherein the drug loading is from 1 to 8.

2. The conjugate according to claim 1 wherein the antibody comprises a VH domain paired with a VL domain, the VH and VL domains having sequences of:

SEQ ID NO. 2 paired with SEQ ID NO. 8.

3. The conjugate according to claim 1 wherein the antibody is an intact antibody.

4. The conjugate according to claim 1 wherein the antibody is humanised, deimmunised or resurfaced.

5. The conjugate according to claim 1 , wherein the drug loading is 1, 2, 3, or 4.

6. A mixture of the conjugates according to claim 1 , wherein the average value of the drug loading is about 2 to about 5.

7. The conjugate according to claim 1 , wherein said conjugate comprises one of more conjugates selected from the group consisting of ConjA, ConjD and ConjE for use in treating a CD19 overexpressing cancer.

8. The conjugate according to claim 7 , wherein the conjugate is ConjE.

9. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient.

10. The pharmaceutical composition of claim 9 further comprising a therapeutically effective amount of a chemotherapeutic agent.

11. A method of treating a CD19 overexpressing cancer comprising administering to a patient the pharmaceutical composition of claim 9 wherein said conjugate comprises one of more conjugates selected from the group consisting of ConjA, ConjD and ConjE.

12. The method of claim 11 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.

13. A method of claim 11 wherein said conjugate is ConjE.

14. The method according to claim 12 , wherein the chemotherapeutic agent is rituximab.

15. The method according to claim 13 , wherein the chemotherapeutic agent is rituximab.

16. The conjugate according to claim 2 , wherein the conjugate is formula ConjE.

Assignments (8)